At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
DFD06 Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open Label, Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption With DFD-06 Cream Versus Clobetasol Propionate Cream, 0.05% in Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating DFD06 Cream and Clobetasol Propionate Cream 0.05% for Psoriasis. Completed, enrolled 50 participants across 15 sites.
Detailed Summary
The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartMay 2014
Primary CompletionApr 2016
Study CompletionAug 2016
TodayJul 2026
First PostedMay 6, 2014
Enrollment StartMay 8, 2014
Primary CompletionApr 1, 2016
Study CompletionAug 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.2 years ago
Interventions
DFD06 Creamdrug
Clobetasol Propionate Cream 0.05%drug